With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.324769-03-1,(3S,5R)-1-Benzyl-3,5-dimethylpiperidin-4-one,as a common compound, the synthetic route is as follows.
Phenyllithium in diisopropyl ether (2 M, 34.5 mL, 690 mmol) was added dropwise to a stirred solution of (3R,5S)-1-benzyl-3,5-dimethylpiperidin-4-one, from preparation 14 (10.0 g, 46 mmol) in anhydrous diethyl ether (150 mL) at -78 C. The mixture was stirred for a further 30 minutes at -78 C., before saturated aqueous ammonium chloride solution (10 mL) was added and the mixture was allowed to warm to room temperature. The organic layer was separated, washed with water (3¡Á200 mL) and dried over sodium sulfate, and then filtered. The solvent was then evaporated to give the crude (3R,4s,5S)-1-benzyl-3,5-dimethyl-4-phenylpiperidin-4-ol (12.8 g) as a white solid. The crude compound was >95% pure by 1H NMR and used directly in preparation 21. LC-MS (ESI+): 296 (M+H); 11H NMR (400 MHz, CD3OD) delta 0.51 (d, 6H), 2.18 (m, 2H), 2.30 (m, 2H), 2.42 (m, 2H), 3.6 (s, 2H), 7.15 (m, 1H), 7.35 (m, 9H)., 324769-03-1
As the paragraph descriping shows that 324769-03-1 is playing an increasingly important role.
Reference£º
Patent; Pfizer Inc; US2005/176772; (2005); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem